MapLight Therapeutics, Inc. MPLT
- Market cap
- $587.7M
- P/E
- 0.0×
Follow MPLT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 12.24 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 21.55 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 109 | 133 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (78) | (161) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (78) | (161) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | (1) | (2) |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (105.38) | (18.56) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (107.06) | (15.91) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | (1.05) | (0.05) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (108.10) | (15.97) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | (263.01) | 52.80 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 1 | 9 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (79) | (138) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | (1) | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | — | (80) | (139) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 99 | 308 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | (109) | (305) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | (194) | 458 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (52.29%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (68.95%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (121.74%) |
ROE
|
|||
MapLight Therapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ACRS Aclaris Therapeutics, Inc. | $589.0M | 0.0× | Compare |
| VALN Valneva SE Sponsored ADR | $589.8M | 65.3× | Compare |
| ALT Altimmune, Inc. | $593.3M | 0.0× | Compare |
| ALLO Allogene Therapeutics, Inc. | $594.2M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OCS Oculis Holding AG | $579.5M | 0.0× | Compare |
| CTMX CytomX Therapeutics, Inc. | $599.2M | 0.0× | Compare |
| MNPR Monopar Therapeutics Inc. | $602.8M | 0.0× | Compare |
| PHAT Phathom Pharmaceuticals, Inc. | $572.8M | 0.0× | Compare |
MapLight Therapeutics, Inc. (MPLT) key facts
- MapLight Therapeutics, Inc. (MPLT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, MPLT traded at $10.46, a market capitalization of $587.7 million.
- Return on equity was −121.7% and debt-to-equity 0.00.
MapLight Therapeutics, Inc. (MPLT) Latest News
13 Aug
MapLight Therapeutics launches $150 million private placement financing. $150 million private placement supplies major capital to fund MapLight operations and development.
MapLight Therapeutics, Inc. announces $150 million private placement financing. $150 million private placement delivers major capital infusion to advance MapLight's pipeline and operations.
MapLight Therapeutics reported second quarter 2026 financial results and provided a business update. Quarterly financial results and business updates typically produce moderately noticeable effects on financial performance perceptions and market sentiment.
29 Jul
MapLight CEO clarifies overlooked details in schizophrenia data that investors failed to note. CEO clarification on schizophrenia data directly addresses investor misperceptions and can shift market sentiment for the company.
28 Jul
MapLight Therapeutics stock crashes on Phase II schizophrenia data. Phase II schizophrenia data triggered immediate stock crash indicating major clinical and financial setback.
27 Jul
MapLight Therapeutics stock plunged 73% after missing on a trial for once-daily dose, wiping out over $1 billion in market cap. Failed clinical trial on once-daily formulation triggers massive market cap loss and questions long-term viability.
MapLight Therapeutics’ schizophrenia drug achieved primary endpoint in Phase II trials. Positive Phase II data marks major clinical milestone likely to boost development pipeline and investor interest.
MapLight Therapeutics reported positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia. Positive Phase 2 schizophrenia trial data can drive major valuation gains and accelerate drug development for MapLight Therapeutics.
30 Jun
MapLight Therapeutics (MPLT) is positioned as a potential biotech opportunity ahead of the ZEPHYR Trial readout. ZEPHYR Trial readout represents a major clinical catalyst capable of significantly shifting company trajectory and investor sentiment.
22 Jun
MapLight Therapeutics announced topline results from its Phase 2 IRIS study of ML-004 in autism spectrum disorder. Phase 2 results for lead asset ML-004 can materially shift valuation, development plans and investor sentiment.
14 May
MapLight Therapeutics, Inc. (MPLT) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business update influence financial performance and market sentiment for the therapeutics company.
1 May
MapLight Therapeutics completed enrollment in its ZEPHYR Phase 2 trial and updated the expected timing for topline results. Completion of Phase 2 enrollment signals progress toward critical topline data, likely driving significant positive impact on valuation and investor interest.
20 Apr
TD Cowen initiates coverage on MapLight Therapeutics (MPLT), stating the stock is undervalued based solely on its schizophrenia program. TD Cowen's bullish initiation highlighting undervaluation on the schizophrenia program alone signals strong investor interest and potential stock re-rating.
12 Apr
MapLight Therapeutics (MPLT) emerges as the premier healthcare stock attracting insider purchases, signaling strong internal confidence. Insider buying reflects optimism that could moderately enhance market sentiment and short-term performance.
26 Mar
MapLight Therapeutics reported fourth quarter and full-year 2025 financial results and provided a business update. Quarterly and annual financial results with business updates significantly affect investor sentiment, stock price, and perceived pipeline progress.
9 Jan
MapLight Therapeutics, Inc. has announced that the expected timing for topline results from its ongoing Phase 2 studies has been updated to Q3 2026. This change may impact the company's development timeline and investor expectations regarding its therapeutic advancements. The delay in topline results could moderately influence investor sentiment and the company's operational focus.
5 Jan
MapLight Therapeutics, Inc. has received Fast Track Designation from the FDA for its investigational drug ML-007C-MA, aimed at treating psychosis associated with Alzheimer's disease. This designation is intended to expedite the development and review process, potentially allowing for quicker access to the treatment for patients. The company is focused on addressing unmet needs in Alzheimer's care, and this regulatory milestone may enhance its position in the market. Fast Track Designation can significantly accelerate the development timeline and market entry for ML-007C-MA, impacting the company's future performance.
16 Dec
MapLight Therapeutics, Inc. has entered into a strategic collaboration with SandboxAQ to discover and develop novel therapies for central nervous system (CNS) disorders. This partnership aims to leverage SandboxAQ's expertise in artificial intelligence and quantum computing to enhance drug discovery processes, potentially accelerating the development of innovative treatments for CNS conditions. The collaboration with SandboxAQ is expected to significantly enhance MapLight's drug discovery capabilities and competitive positioning in the CNS therapy market.
4 Dec
MapLight Therapeutics, Inc. (MPLT) reported its third quarter financial results, highlighting significant corporate progress. The company continues to advance its pipeline and strategic initiatives, focusing on innovative therapies. Financial metrics indicate growth, with increased revenue and reduced losses compared to previous quarters. Management emphasized ongoing research and development efforts aimed at enhancing product offerings and market presence. The report reflects a commitment to long-term goals and shareholder value. The financial results and corporate progress indicate significant strategic moves that could alter the company's trajectory and investor sentiment.
7 Nov
MapLight Therapeutics, Inc. (MPLT) is among several companies experiencing increased attention from activist investors, alongside Gold Royalty and others. These investors are pushing for changes that could influence company strategies and market performance, highlighting a trend of shareholder activism in the biotech sector. Activist investor involvement may moderately influence MapLight's strategic direction and market sentiment.
29 Oct
MapLight Therapeutics has successfully closed its initial public offering (IPO) and the underwriters have fully exercised their option to purchase additional shares. This move is expected to bolster the company's financial position and enhance its market presence. The successful IPO and additional share purchase significantly strengthen the company's financial resources and market positioning.
26 Oct
MapLight Therapeutics has announced the pricing of its initial public offering (IPO), setting the price at $15 per share. The company aims to raise approximately $100 million through the offering, which will be used to advance its pipeline of therapeutics. The IPO is expected to enhance MapLight's financial position and support its growth strategy in the biotechnology sector. The IPO represents a significant strategic move that could enhance the company's financial resources and market position.